ROSGQ (Rosetta Genomics) Research & Development: $2.89 Mil (TTM As of Jun. 2017)


What is Rosetta Genomics Research & Development?

Rosetta Genomics ROSGQ -99.00% Research & Development is $2.89 Mil as of Jun. 2017.

Research & Development is the aggregate amount of research and development expenses during the year. Rosetta Genomics's Research & Development for the six months ended in Jun. 2017 was $1.19 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2017 was $2.89 Mil.

Rosetta Genomics  (OTCPK:ROSGQ) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Rosetta Genomics Research & Development Related Terms

Rosetta Genomics Research & Development Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics Research & Development Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.25 1.74 1.93 2.96 3.16

Rosetta Genomics Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.36 1.60 1.46 1.70 1.19

Rosetta Genomics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2017 adds up the semi-annually data reported by the company within the most recent 12 months, which was $2.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $2.89 Mil mean?
Rosetta Genomics (ROSGQ) has a Research & Development of $2.89 Mil as of Jun. 2017. Research and development expense is the total cost for research and development activities. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' Research & Development too high?
Rosetta Genomics' current Research & Development is $2.89 Mil.
How does Rosetta Genomics' Research & Development compare to TEAR and IDTA?
Rosetta Genomics' Research & Development of $2.89 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Rosetta Genomics and its competitors. Rosetta Genomics's current Research & Development is $2.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Research & Development of $2.89 Mil. The current Research & Development is $2.89 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Research & Development is $2.89 Mil as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.